Chronix Biomedical chronixreport 2004 Page 8
Chroni
Biomedical
Page 8 of 10
Conclusion
The results of the GLT in-house clinical
trials, as shown in Figure 2, are:
1. 65% of at-risk BSE cohort cattle
(N=207)
and
100%
of
BSE
confirmed
cattle
(N=4)
were
reactive.
2. 0.55% of healthy, PrP
res
negative
German
cattle
(N=908)
were
reactive.
Cattle showing repeat reactivity in the
GLT test should be considered at risk for
developing BSE. Further testing will be
required to determine the level of risk an
animal may have for developing BSE.
Because BSE pathogenesis remains
mysterious and there is a medically
acknowledged risk of transmission to
humans, GLT reactive samples should
be handled as potentially infectious until
further testing can confirm its handling
status.
Disclaimer
The clinical study was performed at the
Institute
for
Veterinary
Medicine,
Georg-August University, Gottingen,
Germany, under the direction of
Professor Dr. Dr. B. Brenig, Director.
The GLT Test is not an approved test for
any BSE diagnostic claim. The intended
use of this test is for epidemiologic
purposes only. The data presented in this
report were generated from in-house
clinical data and currently being
reviewed for peer-review publication.
